Plus Therapeutics filings document the company’s CNS oncology pipeline, diagnostic commercialization and public-company governance. Recent Form 8-K disclosures cover REYOBIQ regulatory developments, financial results, executive appointments and compensatory arrangements, board composition, annual meeting mechanics and Nasdaq listing matters.
The filing record also describes capital-structure actions, including the company’s reverse stock split and related charter amendment, as well as proxy disclosures on director elections, shareholder proposals, executive compensation and governance procedures. These filings connect Plus Therapeutics’ radiopharmaceutical development, CNSide diagnostic business, common stock structure and risk-related corporate events within its SEC reporting framework.
van Es-Johansson An reported acquisition or exercise transactions in this Form 4 filing.
PLUS THERAPEUTICS director An van Es-Johansson received new equity awards. On May 14, 2026, the director was granted options to buy 3,686 shares of common stock at $5.76 per share, expiring on May 14, 2036, vesting monthly over 12 months or fully at the 2027 Annual Stockholder Meeting. The director also received 3,686 restricted stock units, each representing one share, vesting in four equal quarterly installments starting July 1, 2026.
Plus Therapeutics director Richard J. Hawkins received new equity awards on May 14, 2026. He was granted stock options for 3,686 shares of common stock at an exercise price of $5.76 per share, expiring on May 14, 2036. He also received 3,686 Restricted Stock Units, each representing one share of common stock.
The RSUs vest in four equal quarterly installments starting on July 1, 2026. The options vest in substantially equal monthly increments over 12 months, and are scheduled to be fully vested at the company’s 2027 Annual Stockholder Meeting, subject to his continued service.
Plus Therapeutics director Kyle Guse reported receiving new equity compensation awards. He was granted stock options covering 3,686 shares of Common Stock at an exercise price of $5.76 per share, expiring on May 14, 2036. These options vest monthly over 12 months and will vest in full at the company’s 2027 Annual Stockholder Meeting, subject to continued service.
He was also granted 3,686 Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The RSUs vest in four equal quarterly installments, starting with one-quarter vesting on July 1, 2026, with the remainder vesting quarterly thereafter. The filing shows no open-market buys or sells, only grants classified as acquisitions.
PLUS THERAPEUTICS, INC. director Howard Clowes reported new equity-based compensation awards. He received a stock option covering 3,686 shares of common stock at an exercise price of $5.76 per share, expiring on May 14, 2036. These options vest in substantially equal monthly installments over 12 months and vest in full at the company’s 2027 annual stockholder meeting if he continues serving through each vesting date.
Clowes was also granted 3,686 Restricted Stock Units, each representing a contingent right to receive one share of common stock. The RSUs vest in four substantially equal quarterly installments, with one-quarter vesting on July 1, 2026 and the remainder vesting quarterly thereafter, subject to continued service. These are non-cash, compensation-related acquisitions rather than open-market share purchases or sales.
PLUS THERAPEUTICS, INC. director Ronald Asbury Andrews reported new equity compensation awards, not open‑market trades. He received stock options for 1,600 shares of Common Stock at an exercise price of $5.76 per share, expiring on May 14, 2036, and an additional option for 3,686 shares at the same exercise price and expiration date.
He also received 3,686 Restricted Stock Units, each representing one share of Common Stock. According to the footnotes, the RSUs vest in four equal quarterly installments starting on July 1, 2026, while one option grant vests monthly over 12 months (with full vesting by the company’s 2027 Annual Stockholder Meeting) and the other vests monthly over 24 months.
PLUS THERAPEUTICS, INC. reported that its Chief Financial Officer, Andrew John Hugh MacIntyre, received new equity awards. He was granted stock options for 3,443 shares of Common Stock at an exercise price of $5.7600 per share, expiring on May 14, 2036. These options vest in substantially equal 1/48th monthly installments over four years and also vest on a change of control as described in his employment agreement.
He also received 3,443 Restricted Stock Units, each representing a right to receive one share of Common Stock. The RSUs vest ratably in 1/12th increments over twelve quarters, starting July 1, 2026, with the remainder vesting quarterly, and his total RSU holdings increased to 30,055 units after this grant.
PLUS THERAPEUTICS, INC. reported that Chief Executive Officer Marc H. Hedrick received new equity-based compensation awards. He was granted options to buy 23,834 shares of common stock at an exercise price of $5.76 per share, along with 23,834 restricted stock units, each representing one share.
The restricted stock units vest in 12 equal quarterly installments, beginning on July 1, 2026
Plus Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where stockholders approved all four proposals presented. The meeting covered director elections, auditor ratification, executive pay and an updated stock incentive plan.
Six directors were elected to terms ending at the 2027 annual meeting, each receiving over 11.8 million votes in favor, with more than 50.8 million broker non-votes recorded. Stockholders ratified CBIZ CPAs, P.C. as independent auditor for 2026 with 60.9 million votes for and 2.3 million against. On an advisory basis, stockholders approved compensation for named executive officers with about 10.4 million votes for and 3.4 million against. They also approved the sixth amendment and restatement of the 2020 Stock Incentive Plan, which received about 8.0 million votes for and 5.6 million against.
Plus Therapeutics, Inc. reported a net loss of $6.9 million for the three months ended March 31, 2026, on grant revenue of $1.0 million, reflecting heavy research and administrative spending as it develops CNS cancer diagnostics and radiopharmaceuticals.
Cash and cash equivalents were $3.0 million with net cash used in operations of $6.2 million, and management states there is substantial doubt about the company’s ability to continue as a going concern without additional financing. Stockholders’ equity increased to $12.0 million, supported by a January 2026 public offering and a 1‑for‑25 reverse stock split that helped the company regain compliance with Nasdaq’s minimum bid requirement.
Plus Therapeutics reported first quarter 2026 results and updated progress on its REYOBIQ radiotherapeutic and CNSide diagnostics businesses. Grant and diagnostic revenue was $1.0 million, slightly below the prior year, while the company recorded a larger operating loss of $7.1 million as it expanded R&D and commercial activities.
Net loss narrowed to $6.9 million, or $1.05 per share, compared with a $17.4 million loss, or $29.86 per share, a year earlier, largely due to the absence of prior-period noncash derivative and financing charges. Cash, cash equivalents, and investments rose to $15.1 million as of March 31, 2026, helped by a $15 million upsized public equity offering completed in January.
Operationally, the company advanced its central nervous system oncology platform by securing FDA Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas, obtaining new reimbursement codes for REYOBIQ delivery and CNSide, adding a second GMP manufacturing site, and expanding payer coverage for CNSide to about 81 million covered lives while scaling commercial infrastructure.